[ad_1]
The moves will reduce annual operating costs by $30 million, and are expected to be substantially completed by the third quarter.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...